Recently, edaravone was approved by the US Food and Drug Administration for the treatment of ALS.498 Edaravone has been shown to inhibit cystine deprivation-induced ferroptosis in mouse hepatoma cells and to protect against ferroptosis induced by SLC7A11 and GPX4 inhibitors.499 Although no studies to date reported the effects of edaravone on ferroptosis in motor neurons in ALS patients or animal models, its antioxidant properties, and its effects on ferroptosis in cell lines suggest that it may help prevent the progression of ALS by inhibiting ferroptosis in motor neurons. This evidence concerns the gene GPX4 and amyotrophic lateral sclerosis.